Applied Pharmaceutical Analysis 2024
In-Person Event
October 7-9, 2024
Bristol Myers Squibb, Cambridge, MA
Regulated Bioanalysis Workshop - Monday, October 7, 2024
Discovery Bioanalysis and New Technologies Workshop - Tuesday, October 8, 2024
Mechanistic ADME Workshop - Wednesday, October 9, 2024
DOWNLOAD APA 2024 PROGRAM GUIDE HERE!
APA 2024 Program
PLENARY LECTURE William Hwang, MD, PhD Assistant Professor @ Harvard Medical School Single-Cell Spatial Dissection Of the Pancreatic Tumor Microenvironment |
PLENARY LECTURE Joe Rajarao, PhD, MBA Senior Manager @ Accenture Application of AI in Drug Development |
||
PLENARY LECTURE Terry Van Vleet, PhD, DABT, FATS, ERT Head of Investigative Toxicology and Pathology @ AbbVie Prospects for New Approach Methodologies and Complex In Vitro Models to Reduce, Refine and Replace Animals in Drug Safety Testing |
PLENARY LECTURE Chongwoo Yu, PhD Office of Clinical Pharmacology (OCP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration Lessons Learned from Regulatory Submissions Involving Endogenous Therapeutic Analyte Bioanalysis: Do You See What I See?
|
||
Yi-Ying Chen, MSc & MSRA Chemist, OSIS, CDER, US Food and Drug Administration Recent Data Integrity Findings in Bioresearch Monitoring |
Nazneen Bano, PhD Regulated BA Immunogenicity & Molecular @ Merck Navigating Challenges in the Development of Neutralizing Antibody Assays: Key Considerations and Strategies |
||
Audrey Arjomandi, PhD Principal Scientist @ Genentech Development of Nonclinical Total Anti-drug Antibody (ADA) Assays to Support The Reproductive Toxicology Studies for Zinpentraxin Alfa |
Jason DelCarpini, PhD Director, Bioanalytical and Molecular Assays @ Moderna Bioanalytical Method Case Studies Across the mRNA-LNP Therapeutic Portfolio |
||
Reilly Eason, PhD Senior Scientist @ Merck Basics of Machine Learning and its Applications in Drug Discovery |
Youhei Kosugi, PhD Associate Director @ Takeda Bio-digital Transformation of Proteomic Analysis |
||
Jeff Lin, PhD Senior Scientist/Large Molecule Bioanalytical Group @ Genentech Characterizing In Vivo Stability of Large Molecule Conjugates Using Complementary Bioanalytical Tools |
Lori Payne, PhD Executive Director of Business Development @ Alturas Analytics "Space - the final microsampling frontier/ Mitra Device /Part II" |
||
Jasleen K. Sodhi, PhD Associate Director of DMPK @ Septerna Recent Advancements in Predicting CYP-Independent Metabolism |
Sandhya Subash, PhD Pharmaceutical Chemistry, Research Associate @ Washington State University Uncertainties and Opportunities in Predicting Non-CYP Mediated Drug Metabolism |
||
Xiaomin Wang, PhD Scientific Director @ BMS Accelerator Mass Spectrometry (AMS) Applications for Supporting Clinical Development |
Kaushik Mitra, PhD Distinguished Scientist, DMPK & Preclinical Safety Assessment, TAL Speciality Ophthalmology JnJ; Adjunct Professor, Med Chem, UMC Mitigation Strategies for Drug-Induced Liver Injury (DILI) - Still an Aspiration? |
||
Xiaoyun Yang, PhD Principal Scientist @ Genentech Implementation of Low Volume Sampling Technologies for PK and Biomarker Analysis: Technical and Logistical Challenges and Solutions |
Long Yaun, PhD Director/Head of Bioanalytical Group @ Biogen A Novel Hybridization LC-MS/MS Methodology for Bioanalysis of siRNA |
||
Elaine Tseng, Principal Scientist @ Pfizer Predicting Clinical Drug-Drug Interactions of Cytochrome P450 Time-Dependent Inhibitors - How Successful Are We? |
Jayaprakasam (Prakash) Bolleddula, PhD Senior Director, Clinical Pharmacology @ iTeos Therapeutics Prediction of Aldehyde Oxidase Mediated Clearance: Recent Progress in Quantitative Translation |
||
Sean Xiaochun Zhu, PhD Scientific Director @ Takeda A 'Missing' Trazpiroben Metabolite Observed As the Most Abundant Metabolite in Human Plasma and Urine |
Milan Kothiya, MS Principal Scientist @ Eli Lilly and Company Measuring Endogenous and Trangene-expressed Protein Levels in Gene Therapy Bioanalytical and Biomarker Studies |
||
Faye Vazvaei, PhD Executive Director of the Regulated PK & ADA Bioanalysis Group @ Merck Research Laboratories; The Evolving Role of Bioanalytical Scientist in Drug Development Beyond ICH-M10 |
Richard Hughes, PhD Scientific Director, Resolian "Domain Specificity In the Tabs and Nabs Assay: Never too late for the characterization of ADA for multi-domain therapeutics" |
||
Qiushi Liu, PhD Scientist Drug Metabolism & Pharmacokinetics @ Takeda Evaluation of Brain Region- and Cell Type-Derived Spatial Knockdown Efficacy of Oligonucleotides Using A Spatial Transcriptomics Platform |
Aihua Liu, PhD Executive Director, Bioanalysis @ Resolian "The Challenges and Solutions in Developing Ultra-sensitive LC-MS Bioanalytical Assay for Oligonucleotides" |
||
Nagendra Chemuturi, PhD Senior Director, ADME @ Eli Lilly The Role of DMPK in non-viral Gene Therapies |
Minu Pilvankar, PhD Principal Scientist @ Boehringer Ingelheim Preclinical To Clinical Translation of ADCs Using PK/PD Modeling |
||
Adam Amaral, Associate Director @ Intellia Therapeutics, Inc. Empirical PK/PD Modeling of Novel In Vivo CRISPR/Cas9 Genome Editiong Therapies |
Maciej Zamek-Gliszczynski, PhD Senior Fellow & Director @ GSK Human ADME Characterization of Linerixibat Reveals Unusual PK Properties: Implication for Clinical Development |
||
Julia Schulz Pauly, PhD PBPK Modeling @ AbbVie Hepatocyte Uptake & Loss Assay (HUpLA): Prof-of-concept Of An All-in-one System for Same Day Measuring Hepatoic Influx, Egress, and Metabolic Clearance Based On the Extended Clearance Concept |
Joyce Liu, PhD Principal Scientist @ Genentech Impact of Missing Metabolites During Lead Optimization in Drug Discovery |
||
Carrie Vyhlidal, PhD Associated Director, CGT @ KCAS Bio PCR-Based Assays for Bioanalysis: Challenges and Latest Recommendations
|
Stefanus J. Steyn, PhD Research Fellow, PK/PD & Metabolism, Inflammation & Immunology PDM Lead @ Pfizer Addressing ProtacTM ADME Challenges |
||
Amanda Leskovar, PhD Director, Project Management @ ICON Laboratory Services Regulatory Inspections From a CRO Perspective - Balancing Guidance, SOP's and Sponsor Direction |
Stephen English, PhD Director, 14C-Bioanalysis @ Pharmaron Qualification of Low Energy Accelerator Mass Spectrometer and Opportunities To Increase Industry Utilization |
||
Syed Ali, PhD Senior Scientist @ Moderna A Comparison of bDNA and RT-qPCR Methodologies for Quantitation of LNP Encapsulated mRNA
|
Tom Zhang, PhD Chief Scientific Officer, Large Molecule Bioanalysis @ Worldwide Clinical Trials Unlocking Bioanalytical Automation: Bridging Development and Practical Application
|
||
Robert Proos, PhD Senior Manager, Metabolomics and Lipidomics Applications @ Sciex Build Resilience and Maintain Unparalleled Sensitivity for Long-Term Bioanalysis
|
|||
APA 2024 Sessions
Regulated Bioanalysis Workshop
Session I: Regulatory and Industry Perspectives on M10 Implementation
Session II: Advances in Sampling Strategies and Drug Delivery Innovations
Session III: Advances in Drug Modalities and Emerging Technologies for Characterization
Session IV: Innovation Junction - Bridging Science and Solutions in Pharma
Poster session
Discovery Bioanalysis and New Technologies Workshop
Session I: Emerging Analytical and Bioanalytical Platform Technology
Session II: Novel Strategies to Advance Biotherapeutic Development
Session III: Innovation Junction - Bridging Science and Solutions in Pharma
Session IV: Recent Case Studies to Support New Modalities
Mechanistic ADME Workshop
Session I: Role of NonCYP enzymes in DDI
Session II: PK/PD Challenges of New Modalities: ADCs, in vivo Gene Therapies, and PROTACs
Session III: The importance of tracking missing metabolites/new technologies (covalent drugs)
Session IV: New Approaches to in Vitro ADME Assays for Improved Drug-Drug-Interaction and Clearance Predictions